Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511287 | 1.00 | CES2 (0.42) | CES2CES1DPP4PDE2APDPK1 | |
| Hydrochloric Acid SCHEMBL1439632 | 0.98 | CES2 (0.41) | CES2CES1DPP4PDE2APDPK1 | |
| Hydrochloric Acid SCHEMBL1439055 | 0.98 | CES2 (0.41) | CES2CES1DPP4PDE2APDPK1 | |
| Hydrochloric Acid SCHEMBL1439060 | 0.98 | CES2 (0.41) | CES2CES1DPP4PDE2APDPK1 | |
| SCHEMBL12498903 | 0.84 | CES2 (0.40) | CES2CES1DPP4PDPK1DPP8 | |
| SCHEMBL20472544 | 0.84 | CES2 (0.40) | CES2CES1DPP4PDPK1DPP8 | |
| SCHEMBL8515216 | 0.84 | DPP4 (0.36) | DPP4PDE2ADPP8 | |
| SCHEMBL8515222 | 0.84 | DPP4 (0.36) | DPP4PDE2ADPP8 | |
| SCHEMBL24262071 | 0.82 | AKR1C3 (0.41) | PDE2A | |
| SCHEMBL5407001 | 0.82 | SLC6A4 (0.42) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3782987-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201297-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | 南京明德新药研发有限公司 | 2019-10-24 | — | — | WO | disclosed |
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| CN-103228649-B | Quinazoline methane amide azetidine | MERCK PATENT GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| EP-2914596-A1 | HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-09-09 | — | — | EP | disclosed |
| CN-104781258-A | Hydroxy-substituted imidazo [1,2-a ] pyridinecarboxamides and their use as soluble guanylate cyclase stimulators | Bayer Pharma AG | 2015-07-15 | — | — | CN | disclosed |
| EP-1246847-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARAMCEUTICAL CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6362182-B1 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; BENIGN PROSTATIC HYPERTROPIC | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-03-26 | — | — | US | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
| US-6218390-B1 | FOR LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, RELAXING LOWER URINARY TRACT TISSUE, THERAPY OF BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, CARDIAC ARRHYTHMIA, SYMPATHETIC MEDIATED PAIN, MIGRAINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| WO-2001022919-A2 | SPIRO[BICYCLIC -AZACYCLOALKYL AND -CYCLOALKYL] DERIVATIVES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999025345-A1 | ALPHA-1A ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | CES2 4166/4885CES1 1332/4885DPP4 2858/4885 |
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | ROCK1, ROCK2, CIT | CES2 4205/4885CES1 1510/4885DPP4 3918/4885 |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | CES2 4205/4885CES1 1510/4885DPP4 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.